However, aberrant expression or activation of c-MET has been implicated in several malignancies such as breast, liver, lung, colorectal, and gastric cancers, making it an attractive target for therapeutic intervention (Goyal et al., 2013; Hack et al., 2014; Ichimura et al., 1996; Zhang et al., 2020). Here, MET is linked to gastric cancer.